Roivant Sciences has launched a new biopharma company named Respivant Sciences which will focus on developing innovative therapeutics for serious respiratory diseases. The new biopharma company of Roivant Sciences will be headed by Bill Gerhart – CEO, Ahmet Tutuncu – Executive Vice President for Clinical and Regulatory, and Pravin Soni – Executive Vice President for […]
Continue reading …Urovant Sciences has acquired global licensing rights for the development and commercialization of a gene therapy called hMaxi-K from Ion Channel Innovations, which is being developed for the treatment of overactive bladder (OAB) in patients who did not respond to oral pharmacologic therapy. As of now, there are no treatments for overactive bladder that have […]
Continue reading …Swiss drugmaker Novartis unveiled new data on Entresto (sacubitril/valsartan) from a phase 4 study which confirms that the heart failure drug can be initiated early and safely across a broad range of heart failure patients with reduced ejection fraction (HFrEF), whose condition has been stabilized following hospitalization because of an acute heart failure episode. In […]
Continue reading …Novartis has agreed to acquire the exclusive global development and marketing rights of atopic dermatitis drug MOR106 from MorphoSys and Galapagos in a deal that could go up to $1.1 billion. The Swiss drugmaker will make an upfront payment of €95 million ($111 million) to Galapagos and MorphoSys apart from potential milestone payments of up […]
Continue reading …